98%
921
2 minutes
20
Liver cancer presents unique challenges due to its systemic impact and complex treatment modalities. Patients often experience a range of complications, including cardiovascular, renal, hematological, and metabolic abnormalities, which can significantly affect treatment outcomes and quality of life. This article emphasizes the integration of multidisciplinary strategies and artificial intelligence-driven diagnostics, which have the potential to improve patient outcomes by optimizing early detection and targeted management of these complications. A recent study on 60 liver cancer patients undergoing interventional therapy highlighted the importance of recognizing and managing these complications. This article offers an overview of systemic complications in liver cancer, focusing on pathophysiological mechanisms, risk factors, and strategies to improve care. By addressing gaps in the existing literature and proposing future research directions, it underscores the importance of comprehensive, patient-centered approaches to refine therapeutic strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188556 | PMC |
http://dx.doi.org/10.4240/wjgs.v17.i6.104883 | DOI Listing |
Cancer Epidemiol Biomarkers Prev
September 2025
National Cancer Institute, Bethesda, MD, United States.
Background: Alcohol consumption is a risk factor for certain cancers and is increasing in the United States. We estimated the impact of alcohol consumption on cancer incidence trends in the United States from 2008-2019 across six alcohol-related cancers among men and women.
Methods: Average daily alcohol consumption (ADC) was calculated from the National Health Interview Survey (NHIS, 1998-2009) and adjusted to per capita sales data to account for underreporting alcohol use.
Metab Brain Dis
September 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Acute or chronic liver damage can result in Hepatic Encephalopathy (HE), a potentially fatal neuropsychiatric condition that leads to cerebral and neurological alterations. Dapagliflozin (DAPA), an orally active Sodium/Glucose cotransporter 2 inhibitor with long duration of action. The study aim was to evaluate the potential protective impact of DAPA against HE caused by Thioacetamide (TAA) in rats.
View Article and Find Full Text PDFPediatr Blood Cancer
September 2025
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Background: The suppressor of tumorigenesis 2 (ST2) has emerged as one of the most promising biomarkers for predicting mortality of acute graft-versus-host disease (aGvHD) when measured at the onset of symptoms, but detailed time course studies are needed to understand the potential of ST2 as a risk marker of both aGvHD and chronic graft-versus-host disease (cGvHD), potentially allowing pre-emptive adjustment of immunosuppressive treatment.
Procedure: We measured ST2 levels in 117 children undergoing standard hematopoietic stem cell transplantation (HSCT) before conditioning and at regular intervals post-HSCT.
Results: ST2 levels were significantly increased from Day +7 in patients developing aGvHD of any grade (no GvHD: 23.
Liver Int
October 2025
The Global NASH Council, Washington, DC, USA.
Background: The Middle East and North Africa (MENA) region is undergoing demographic shifts potentially increasing metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications. We assessed MASLD prevalence and liver disease burden from 2010 to 2021.
Methods: Data from Global Burden of Disease (GBD), United Nations Population Division and NCD Risk Factor Collaboration covering 21 MENA countries were used for annual percent change (APC) trends per Joinpoint regression.
Liver Int
October 2025
Division of Gastroenterology and Hepatology, Department of Medicine, The Institute for Bioelectronic Medicine, Feinstein Institutes for Medical Research & Cold Spring Harbor Laboratory, Northwell Health, Manhasset, New York, USA.
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths, primarily due to late-stage diagnosis. In this multicenter study, our goal is to identify functional biomarkers that stratify the risk of HCC in patients with cirrhosis (CP) for early diagnosis.
Methods: Five thousand and eight serum proteins (Somascan) were analysed in Cohort A (477 CP, including 125 HCC).